136 related articles for article (PubMed ID: 22576740)
21. Heregulin regulates the actin cytoskeleton and promotes invasive properties in breast cancer cell lines.
Hijazi MM; Thompson EW; Tang C; Coopman P; Torri JA; Yang D; Mueller SC; Lupu R
Int J Oncol; 2000 Oct; 17(4):629-41. PubMed ID: 10995872
[TBL] [Abstract][Full Text] [Related]
22. Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy.
Girgert R; Emons G; Gründker C
Breast Cancer Res Treat; 2012 Jul; 134(1):199-205. PubMed ID: 22290080
[TBL] [Abstract][Full Text] [Related]
23. HER2/HER3 regulates extracellular acidification and cell migration through MTK1 (MEKK4).
Sollome JJ; Thavathiru E; Camenisch TD; Vaillancourt RR
Cell Signal; 2014 Jan; 26(1):70-82. PubMed ID: 24036211
[TBL] [Abstract][Full Text] [Related]
24. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells.
Albanito L; Madeo A; Lappano R; Vivacqua A; Rago V; Carpino A; Oprea TI; Prossnitz ER; Musti AM; Andò S; Maggiolini M
Cancer Res; 2007 Feb; 67(4):1859-66. PubMed ID: 17308128
[TBL] [Abstract][Full Text] [Related]
25. Involvement of heregulin-beta2 in the acquisition of the hormone-independent phenotype of breast cancer cells.
Tang CK; Perez C; Grunt T; Waibel C; Cho C; Lupu R
Cancer Res; 1996 Jul; 56(14):3350-8. PubMed ID: 8764133
[TBL] [Abstract][Full Text] [Related]
26. Bidirectional interactions between the estrogen receptor and the cerbB-2 signaling pathways: heregulin inhibits estrogenic effects in breast cancer cells.
Grunt TW; Saceda M; Martin MB; Lupu R; Dittrich E; Krupitza G; Harant H; Huber H; Dittrich C
Int J Cancer; 1995 Nov; 63(4):560-7. PubMed ID: 7591267
[TBL] [Abstract][Full Text] [Related]
27. Heregulin negatively regulates transcription of ErbB2/3 receptors via an AKT-mediated pathway.
Awasthi S; Hamburger AW
J Cell Physiol; 2014 Nov; 229(11):1831-41. PubMed ID: 24692179
[TBL] [Abstract][Full Text] [Related]
28. The activation of G protein-coupled receptor 30 (GPR30) inhibits proliferation of estrogen receptor-negative breast cancer cells in vitro and in vivo.
Wei W; Chen ZJ; Zhang KS; Yang XL; Wu YM; Chen XH; Huang HB; Liu HL; Cai SH; Du J; Wang HS
Cell Death Dis; 2014 Oct; 5(10):e1428. PubMed ID: 25275589
[TBL] [Abstract][Full Text] [Related]
29. Essential role for Rac in heregulin beta1 mitogenic signaling: a mechanism that involves epidermal growth factor receptor and is independent of ErbB4.
Yang C; Liu Y; Lemmon MA; Kazanietz MG
Mol Cell Biol; 2006 Feb; 26(3):831-42. PubMed ID: 16428439
[TBL] [Abstract][Full Text] [Related]
30. Estradiol and tamoxifen induce cell migration through GPR30 and activation of focal adhesion kinase (FAK) in endometrial cancers with low or without nuclear estrogen receptor α (ERα).
Tsai CL; Wu HM; Lin CY; Lin YJ; Chao A; Wang TH; Hsueh S; Lai CH; Wang HS
PLoS One; 2013; 8(9):e72999. PubMed ID: 24039841
[TBL] [Abstract][Full Text] [Related]
31. GPR30 expression and function in breast cancer cells are induced through a cis‑acting element targeted by ETS factors.
Segura-Bautista D; Olivares A; Casas-González P; Bonilla E; Salazar Z; Pérez-Solis MA
Oncol Rep; 2020 May; 43(5):1669-1682. PubMed ID: 32323852
[TBL] [Abstract][Full Text] [Related]
32. Heregulin Drives Endocrine Resistance by Altering IL-8 Expression in ER-Positive Breast Cancer.
Papadimitropoulou A; Vellon L; Atlas E; Steen TV; Cuyàs E; Verdura S; Espinoza I; Menendez JA; Lupu R
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33086721
[TBL] [Abstract][Full Text] [Related]
33. GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer.
Mo Z; Liu M; Yang F; Luo H; Li Z; Tu G; Yang G
Breast Cancer Res; 2013 Nov; 15(6):R114. PubMed ID: 24289103
[TBL] [Abstract][Full Text] [Related]
34. Heregulin induces transcriptional activation of the progesterone receptor by a mechanism that requires functional ErbB-2 and mitogen-activated protein kinase activation in breast cancer cells.
Labriola L; Salatino M; Proietti CJ; Pecci A; Coso OA; Kornblihtt AR; Charreau EH; Elizalde PV
Mol Cell Biol; 2003 Feb; 23(3):1095-111. PubMed ID: 12529413
[TBL] [Abstract][Full Text] [Related]
35. Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage.
Menendez JA; Mehmi I; Lupu R
Int J Oncol; 2005 Mar; 26(3):649-59. PubMed ID: 15703820
[TBL] [Abstract][Full Text] [Related]
36. Significance of integrin αvβ5 and erbB3 in enhanced cell migration and liver metastasis of colon carcinomas stimulated by hepatocyte-derived heregulin.
Yoshioka T; Nishikawa Y; Ito R; Kawamata M; Doi Y; Yamamoto Y; Yoshida M; Omori Y; Kotanagi H; Masuko T; Enomoto K
Cancer Sci; 2010 Sep; 101(9):2011-8. PubMed ID: 20626753
[TBL] [Abstract][Full Text] [Related]
37. Epidermal growth factor induces G protein-coupled receptor 30 expression in estrogen receptor-negative breast cancer cells.
Albanito L; Sisci D; Aquila S; Brunelli E; Vivacqua A; Madeo A; Lappano R; Pandey DP; Picard D; Mauro L; Andò S; Maggiolini M
Endocrinology; 2008 Aug; 149(8):3799-808. PubMed ID: 18467441
[TBL] [Abstract][Full Text] [Related]
38. Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness.
Lewis GD; Lofgren JA; McMurtrey AE; Nuijens A; Fendly BM; Bauer KD; Sliwkowski MX
Cancer Res; 1996 Mar; 56(6):1457-65. PubMed ID: 8640840
[TBL] [Abstract][Full Text] [Related]
39. Inhibitory effect of (-)-epigallocatechin and (-)-epigallocatechin gallate against heregulin beta1-induced migration/invasion of the MCF-7 breast carcinoma cell line.
Kushima Y; Iida K; Nagaoka Y; Kawaratani Y; Shirahama T; Sakaguchi M; Baba K; Hara Y; Uesato S
Biol Pharm Bull; 2009 May; 32(5):899-904. PubMed ID: 19420761
[TBL] [Abstract][Full Text] [Related]
40. The HER2- and heregulin β1 (HRG)-inducible TNFR superfamily member Fn14 promotes HRG-driven breast cancer cell migration, invasion, and MMP9 expression.
Asrani K; Keri RA; Galisteo R; Brown SA; Morgan SJ; Ghosh A; Tran NL; Winkles JA
Mol Cancer Res; 2013 Apr; 11(4):393-404. PubMed ID: 23378579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
